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Abstract
Background: Curcuma comosa Roxb. (C. comosa) is an indigenous medicinal herb that has been used in Thailand
as a dietary supplement to relieve postmenopausal symptoms. Recently, a novel phytoestrogen, (3R)-1,7-diphenyl-
(4E,6E)-4,6-heptadien-3-ol or compound 049, has been isolated and no study thus far has investigated the role of C.
comosa in preventing metabolic alterations occurring in estrogen-deprived state. The present study investigated
the long-term effects (12 weeks) of C. comosa hexane extract and compound 049 on insulin resistance in
prolonged estrogen-deprived rats.
Methods: Female Sprague-Dawley rats were ovariectomized (OVX) and treated with C. comosa hexane extract (125
mg, 250 mg, or 500 mg/kg body weight (BW)) and compound 049 (50 mg/kg BW) intraperitoneally three times
per week for 12 weeks. Body weight, food intake, visceral fat weight, uterine weight, serum lipid profile, glucose
tolerance, insulin action on skeletal muscle glucose transport activity, and GLUT-4 protein expression were
determined.
Results: Prolonged ovariectomy resulted in dyslipidemia, impaired glucose tolerance and insulin-stimulated skeletal
muscle glucose transport, as compared to SHAM. Treatment with C. comosa hexane extract and compound 049,
three times per week for 12 weeks, markedly reduced serum total cholesterol and low-density lipoprotein levels,
improved insulin sensitivity and partially restored uterine weights in ovariectomized rats. In addition, compound
049 or high doses of C. comosa hexane extract enhanced insulin-mediated glucose uptake in skeletal muscle and
increased muscle GLUT-4 protein levels.
Conclusions: Treatment with C. comosa and its diarylheptanoid derivative improved glucose and lipid metabolism
in estrogen-deprived rats, supporting the traditional use of this natural phytoestrogen as a strategy for relieving
insulin resistance and its related metabolic defects in postmenopausal women.
Background
Insulin resistance syndrome is a complex metabolic
abnormality of peripheral tissues in response to insulin.
The main features of this syndrome include insulin
resistance of skeletal muscle glucose metabolism,
impaired glucose tolerance, compensatory hyperinsuline-
mia, essential hypertension, central obesity, and athero-
genic dyslipidemia [1]. Postmenopausal women are at a
greater risk for developing type 2 diabetes [2], a meta-
bolic disorder characterized by glucose intolerance and
insulin resistance. These metabolic conditions in post-
menopausal women are usually accompanied by weight
gain, obesity, and increased inflammation [3-5]. In addi-
tion, an increase in mortality associated with type 2 dia-
betes and cardiovascular disease has been directly
attributed to insulin resistance and hyperinsulinemia [6].
Importantly, estrogen replacement can attenuate the
increased risk for type 2 diabetes in postmenopausal
women and improve whole body glucose metabolism
[2,7], suggesting a critical role of estrogen in regulating
glucose homeostasis. However, clinical studies on hor-
mone replacement therapy in postmenopausal women
have raised concerns about an increased risk of breast
cancer and an unacceptable rate of unfavorable
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replacement strategies is an issue of increasing impor-
tance for postmenopausal women.
Phytoestrogens are naturally occurring non-steroidal
plant-derived compounds with diverse structures which
are found in many fruits, vegetables, and grains [9]. Stu-
dies on dietary phytoestrogens intake in postmenopausal
women have indicated that high phytoestrogens intake
is associated with a favorable metabolic cardiovascular
risk profile, such as reduced plasma lipids and decreased
aortic stiffness [10,11]. In addition, the use of phytoes-
trogens as an alternative intervention has been sup-
ported by evidences that incidence of menopausal
symptoms and of breast and endometrial cancers are
lower in Asian women who have a diet rich in soy pro-
ducts [12,13]. Plant-derived phytoestrogens are, there-
fore, considered to be an alternative remedy to prevent
the development of metabolic defects in postmenopausal
women.
Curcuma comosa Roxb. (Zingiberaceae) has been tra-
ditionally used in indigenous medicine in Thailand as a
dietary supplement to relieve a variety of unpleasant
peri- and postmenopausal symptoms. The hexane
extract of C. comosa rhizome exhibited hypocholestero-
lemic [14,15] and anti-inflammatory activity [16,17].
Furthermore, treatment with C. comosa hexane extract
improved the spatial memory of post-training [18] and
effectively prevented bone loss in ovariectomized
rodents [19]. The unique pharmacological actions of C.
comosa underscore its therapeutic potential in relieving
menopausal symptoms. Recently, the hexane extract of
C. comosa and its isolated compound, a diarylheptanoid
or (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol (here-
after referred to as compound 049) have been demon-
strated to have estrogenic activity [20,21]. Despite the
long-term and widespread use of C. comosa extract, to
date, no studies have been conducted to investigate its
potential to reduce the risks of diabetes and cardiovas-
cular disease in postmenopausal women. Therefore, the
present study was undertaken to investigate the long-
term (12 weeks) effects of C. comosa extract and com-
pound 049 on metabolic alterations in rats with ovar-
iectomy-induced insulin resistance. The results of this
study provide mechanistic insight into the favorable
effects of these compounds being used as an alternative
strategy for relieving insulin resistance and its related
metabolic defects in postmenopausal women.
Materials and methods
Chemicals
2-[1,2-
3 H] deoxyglucose (300 μCi/mmol), [U-
14 C]
mannitol (0.8 μCi/mmol), and Ultima Gold™ scintilla-
tion cocktail were obtained from PerkinElmer Life
Sciences (Boston, MA, USA), chemicals for the
bicinchoninic acid (BCA) protein assay and bovine
serum albumin were obtained from Sigma Chemical
(St. Louis, MO, USA), Human R insulin (Insulin,
Human Recombinant) from Eli Lilly (Indianapolis, IN,
USA), ketamine from Gedeon Richter (Budapest, Hun-
gary), xylazine from Farvet Laboratories (Bladel, The
Netherlands), polyclonal anti-GLUT-4 antibody from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), and
rabbit horseradish peroxidase-conjugated (IgG-HRP)
secondary antibody and enhanced chemiluminescence
(ECL) reagent from Cell Signaling Technology (Bev-
erly, MA, USA). The glucose assay kit was obtained
from Gesellschaft fur Biochemica und Diagnostica
(Wiesbaden, Germany) and insulin radioimmunoassay
kit from Linco Research (St. Charles, MO, USA). Pre-
cast polyacrylamide gels were purchased from Pierce
(Perbio Science, Cambrigde, England).
C. comosa plant extract and compound 049 isolation
C. comosa rhizomes were collected from the Kampaeng-
saen district, Nakorn Pathom province, Thailand. A vou-
cher herbarium specimen has been deposited at the
Department of Plant Science, Faculty of Science, Mahi-
dol University, Bangkok (SCMU No. 300) [22]. Prepara-
tion of the C. comosa plant extracts were performed as
previously reported [20]. Briefly, the rhizomes were
sliced, dried, and ground to a powder. The powder was
successively extracted with n-hexane and the solvent
was removed in vacuo.F o rt h eh e x a n ee x t r a c t ,ap a l e -
brown viscous oil was obtained. This hexane extract was
dissolved in corn oil for animal treatment. Characteriza-
tion and standardization of the extract used in this
study was conducted using reversed-phase HPLC (col-
umn: Prodigy ODS-3, 250 mm×4.6 mm, 5 μ,1 0 0Å ;
mobile phase: water-acetonitrile; detection at 260 nm),
revealing a major diarylheptanoid (23.9%), (3R)-1,7-
diphenyl-(4E,6E)-4,6-heptadien-3-ol (compound 049)
(Figure 1). Compound 049 was isolated from the hexane
extract as a major component by repeated silica gel col-
umn chromatography eluting with hexane/dichloro-
methane; each step utilized an increasing quantity of the
more polar solvent.
Figure 1 Structure of (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-
ol: compound 049.
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Animal procedures were approved by the Animal Care
and Use Committee, Faculty of Science, Mahidol Uni-
versity, in accordance with the International Guiding
Principles for Biomedical Research Involving Animals of
Council for International Organizations of Medical
Sciences (CIOMS). Adult female Sprague-Dawley rats
(8-weeks-old), weighing between 180-200 g, supplied by
the National Laboratory Animal Center, Thailand, were
housed individually in 8 × 10 inch hygienic hanging
metabolic cages at the Center of Animal Facilities,
Faculty Science, Mahidol University. Animals were given
standard rat chow and water ad libitum. The housing
unit was maintained at 22-23°C with a 12/12 h light/
dark cycle. Body weight was recorded every other day.
The amount of food intake for each animal was mea-
sured over a 24 h period, and measurements were con-
ducted at least 3 times per week. Rats were randomly
assigned to either sham operation (SHAM, n = 8) or
bilateral ovariectomy (OVX, n = 40). Animals were
allowed to recuperate for 7 days after surgery. Ovariec-
tomized animals were randomly divided into one of the
following five groups: OVX-control (OVX), OVX receiv-
ing C. comosa h e x a n ee x t r a c ta tad o s eo f1 2 5m g / k g
body weight (BW) (OVX + C-125), OVX receiving 250
mg C. comosa extract/kg BW (OVX + C-250), OVX
receiving 500 mg C. comosa extract/kg BW (OVX + C-
500), and OVX receiving (3R)-1,7-diphenyl-(4E,6E)-4,6-
heptadien-3-ol (compound 049) at dose of 50 mg/kg
BW (OVX + 049). The C. comosa-treated animals were
intraperitoneally administered 0.1 mL of the C. comosa
hexane extract or compound 049 diluted in corn oil.
SHAM and OVX-control rats received vehicle (0.1 mL
corn oil). Treatment and vehicle were administered
three times per week for 12 weeks.
Determination of whole body insulin sensitivity
Oral glucose tolerance test (OGTT) was performed to
assess insulin sensitivity at the whole-body level. Fol-
lowing a 12-week treatment period, an OGTT was per-
formed on each animal. In the evening (1800 h) of the
day before the test, rats were food-restricted to 4 g of
chow. On the day of the test (0900 h), blood sample
were collected from tail veins before and after glucose
feeding (1 g/kg BW) at 15, 30, 60, and 90 min. Blood
sample were mixed with EDTA and centrifuged at
13000 g at 4°C for 1 min. Plasma was kept at -80°C
and used for glucose and insulin determination. The
area under the curve for glucose (glucose AUC) or
insulin (insulin AUC) was calculated. Subsequently, the
glucose-insulin (G-I) index was calculated, as the pro-
duct of the respective glucose and insulin AUCs, and
is inversely related to whole-body insulin sensitivity
[23].
Assessment of muscle glucose transport activity
As skeletal muscle is the major tissue accounting for 70-
85% of whole-body glucose disposal following a glucose
challenge [24], insulin action on glucose transport activ-
ity was determined in skeletal muscle under basal and
insulin-stimulated conditions using 2-deoxy-[
3 H]-glu-
cose (2-DG) uptake. Five days after OGTT, animals
were food-restricted as described above. At 0800 h, ani-
mals were weighed and anesthetized by intraperitoneal
administration of a mixture of ketamine (50 mg/kg BW)
and xylazine (10 mg/kg BW). Soleus muscle was iso-
lated, divided into two portions of approximately 20-25
mg, and incubated for 60 min at 37°C in 3 mL of oxyge-
nated Krebs-Henseleit Buffer (KHB) supplemented with
8 mM D-glucose, 32 mM D-mannitol and 0.1% radioim-
munoassay-grade bovine serum albumin (BSA). One
strip of soleus muscle was incubated in the absence of
insulin, and the other strip in the presence of a maxi-
mally effective concentration of insulin (2 mU/mL).
Flasks were continuously gassed with a mixture of 95%
O2 and 5% CO2 throughout the incubation and trans-
port study procedures. After the first incubation period,
each muscle strip was rinsed for 10 min at 37°C in 3
mL of oxygenated KHB containing 40 mM D-mannitol,
0.1% BSA and insulin (for the muscle strip in the pre-
sence of insulin). Each muscle strip was then incubated
f o r2 0m i na t3 7 ° Ci n2m Lo fK H Bc o n t a i n i n g1m M
2-[1,2-
3 H] deoxyglucose (2-DG), 39 mM [U-
14 C] man-
nitol, 0.1% BSA and insulin (for the muscle strip in the
presence of insulin). At the end of the incubation per-
iod, muscle strips were removed and trimmed of excess
fat and connective tissue, immediately frozen with liquid
nitrogen and weighed. Frozen muscles were solubilized
i n0 . 5m Lo f0 . 5MN a O H ,a n d1 0m Lo fs c i n t i l l a t i o n
cocktail was added. Specific intracellular accumulation
of 2-DG was determined as previously described [25]
using mannitol to correct for extracellular accumulation
of 2-DG. Glucose transport activity was measured by
determination of the intracellular accumulation of 2-DG
(pmol/mg muscle wet weight/20 min). Contralateral
soleus muscle was also removed, trimmed of fat and
connective tissue, quickly frozen in liquid nitrogen, and
used for GLUT-4 protein level determination.
Serum lipid measurements
Following muscle dissection, blood was collected from
the abdominal vein. Whole blood was allowed to clot
and then centrifuged at 3000 g for 20 min to obtain
serum. Serum levels of total cholesterol (TC), high-den-
sity lipoprotein cholesterol (HDL), and low-density lipo-
protein cholesterol (LDL) were measured by enzymatic
methods using an automated analyzer (Dimension RxL
Max, DADE Behring, Marburg, Germany). Immediately
after blood sample collection, visceral fat was collected
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and the uterus was removed and weighed.
Muscle GLUT-4 protein content
Glucose uptake into skeletal muscle under insulin-sti-
mulated condition is mediated by GLUT-4 protein [26].
To examine whether changes in insulin action on skele-
tal muscle glucose transport due to C. comosa treatment
is associated with GLUT-4 protein expression, muscle
GLUT-4 protein levels were evaluated. Portions of
soleus muscle were homogenized as previously described
[27]. These homogenates were used for total protein
determination, solubilized, separated by electrophoresis
using a 12% pre-cast polyacrylamide gel and transferred
onto nitrocellulose paper. Protein blots were incubated
with polyclonal anti-GLUT-4 antibody, GAPDH and
subsequently with IgG-HRP secondary antibody. Protein
b a n d sw e r ev i s u a l i z e db yE C Lo nh y p e rf i l m .I m a g e s
were digitized and band intensities quantified using
Image Master Totallab Software, version 3.0 (Amersham
Pharmacia Biotech, Sweden).
Statistical analysis
All values were expressed as the mean ± SE. Differences
among groups were determined using a one-way analy-
sis of variance (ANOVA) with Tukey’s multiple compar-
ison post-test using SPSS program version 16.0. A value
of P < 0.05 was considered to be statistically significant.
Results
Body and tissue weight and food intake
Twelve weeks following ovariectomy, OVX rats dis-
played significant weight gain compared to SHAM ani-
mals (Figure 2A). Body weight gain observed in OVX
rats was significantly reversed by C. comosa extract
treatment. Food intake, based on the accumulated aver-
age daily food intake throughout the 12-week experi-
mental period, was significantly higher in OVX rats
compared to either SHAM rats or OVX rats treated
with C. comosa extract (Figure 2B). In contrast to the
effects of C. comosa extract, compound 049 treatment
did not affect body weight gain or food intake in OVX
rats. Comparison of OVX rats with SHAM rats showed
a 22% increase in visceral fat content, which was signifi-
cantly reversed by treatment with either C. comosa
extract or compound 049 (Figure 2C). The reduction in
uterine weight in OVX rats was also partially recovered
by treatment with either C. comosa extract or com-
pound 049 (Figure 2D).
Serum lipid profile
Compared to SHAM rats, OVX rats displayed a signifi-
cant increase in TC (36%) and LDL (45%), but not
HDL, whereas treatment with either C. comosa extract
or compound 049 significantly reduced both TC levels
(19-37%) and LDL levels (27-45%) (Figures 3A-C). C.
comosa extract or compound 049 treatment resulted in
a significant reduction in the LDL/TC ratio in OVX rats
(Figure 3E). Interestingly, treatment with either C.
comosa extract or compound 049 significantly improved
the HDL/TC ratio when compared to the SHAM and
OVX groups (Figure 3D).
OGTT response
Following glucose feeding (1 g/kg BW), there was no
significant difference in plasma glucose levels among all
groups throughout the experimental period (Figure 4A).
However, 15-min after glucose challenge, plasma insulin
levels in OVX rats were higher than those in other
experimental groups (Figure 4B). Compared with the
SHAM group, OVX rats displayed a significant rise in
both insulin AUC (38%, Figure 4D) and G-I index (49%,
Figure 4E). These elevated insulin AUC and G-I index
values observed in the OVX group were reduced follow-
ing treatment with either C. comosa extract (39-44%,
Figure 4D) or compound 049 (28-34%, Figure 4E).
Muscle glucose transport and GLUT-4 protein levels
Skeletal muscle is the major tissue responsible for
whole-body glucose disposal following a glucose chal-
lenge [24]. Thus, the effects of C. comosa and com-
pound 049 treatment on insulin-stimulated glucose
transport activity and on total GLUT-4 protein levels in
skeletal muscle were studied. Basal 2-deoxy-[
3 H]-glu-
cose (2-DG) uptake was comparable among the experi-
mental groups (Figure 5A). Compared to the SHAM
group, insulin-mediated 2-DG transport rates in soleus
muscle isolated from OVX rats was reduced by 35%
(Figure 5B). A significant improvement in insulin-
mediated 2-DG uptake was observed in the OVX rats
receiving either C-500 (16%) or compound 049 (45%)
(Figure 5B). Twelve weeks following ovariectomy, total
GLUT-4 protein levels in soleus muscle were reduced
by 33% in OVX rats (Figure 5C). Treatment with either
C-500 or compound 049 significantly restored GLUT-4
protein levels in soleus muscle by 17% and 47%, respec-
tively (Figure 5C).
Discussion
The present study demonstrated the protective effects of
C. comosa, a novel natural phytoestrogen, against the
risks of diabetes and cardiovascular disease in rats under
estrogen-deprivation conditions. The evidence presented
in this study corroborates the traditional use of C.
comosa in relieving unpleasant symptoms in postmeno-
pausal women including the metabolic defects. More-
over, this study indicates that these favorable effects
observed following C. comosa extract treatment in the
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Figure 2 Final body weight, food intake, visceral fat weight and uterine weight of sham operated control (SHAM) and ovariectomized
(OVX) rats treated with or without C. comosa hexane extract at 125 mg (OVX + C-125), 250 mg (OVX + C-250), and 500 mg (OVX + C-
500) per kg body weight or 50 mg of compound 049 per kg body weight (OVX + 049). Final body weight (A); accumulated amount of
food intake (B); visceral fat weight (C); uterine weight (D). Values are reported as the mean ± SE for 8 animals/group. *P < 0.05 vs. SHAM group;
†P < 0.05 vs. OVX group; #P < 0.05 vs. OVX + 049; §P < 0.05 vs. all other groups.
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Figure 3 Serum lipid levels of sham operated control (SHAM) and ovariectomized (OVX) rats treated with or without C. comosa
hexane extract or compound 049. Animals are as described in legend of Figure 2. (A) total; (B) high-density lipoprotein (HDL) cholesterol; (C)
low-density lipoprotein (LDL) cholesterol; (D) ratio of HDL to total cholesterol (HDL/total); and (E) ratio of LDL to total cholesterol (LDL/total).
Values are reported as the mean ± SE for 8 animals/group. *P < 0.05 vs. SHAM group; †P < 0.05 vs. OVX group.
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and ovariectomized (OVX) rats treated with or without C. comosa hexane extract or compound 049. Animals are as described in legend
of Figure 2. (A) 2-deoxyglucose uptake in the absence (blank bar) and presence (filled bar) of insulin (2 mU/ml); (B) net increase above basal
level for 2-deoxyglucose uptake due to insulin; (C) whole muscle GLUT-4 protein levels. GLUT-4 levels were normalized by GAPDH. Values are
reported as the mean ± SE for 7-8 animals/group. *P < 0.05 vs. SHAM group; †P < 0.05 vs. OVX group.
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actions including its estrogenic and anti-inflammatory
properties, and its diarylheptanoid derivative is at least
accounted for the effects.
The role of estrogen in the regulation of glucose
homeostasis has been shown previously. For example,
postmenopausal women are at risk for increased inci-
dence of obesity, type 2 diabetes, cardiovascular disease,
and insulin resistance syndrome [5,28,29], whereas
estrogen therapy reduces the incidence of insulin resis-
tance and type 2 diabetes risks [30,31]. Insulin resistance
develops when there is no estrogen in aromatase-knock-
out mice [32]. Hepatic insulin resistance and impaired
skeletal muscle GLUT-4 expression are accounted for
the impaired glucose tolerance and reduced insulin sen-
sitivity in estrogen receptor alpha (ERa)k n o c k o u tm i c e
[ 3 3 , 3 4 ] .D u et oo v a r i a nh o r m o n ed e p l e t i o n ,O V Xr a t
becomes hyperphagic and gains weight with an increase
in visceral fat accumulation [35,36]. In this study, adult
female rats subjected to prolonged (12-week) ovariect-
omy were used to assess the metabolic impact of estro-
gen deprivation with C. comosa treatment in the
postmenopausal state. We have previously reported that
prolonged ovariectomy leads to the development of sys-
temic metabolic conditions displaying key features of
insulin resistance syndrome, such as increased visceral
fat content, dyslipidemia, impaired glucose tolerance
and decreased insulin-mediated glucose uptake in skele-
tal muscle [37]. These metabolic alterations in OVX rats
were attenuated by estrogen replacement [37]. In this
study, we observed that treatment of OVX rats with C.
comosa extract, at all doses tested (125 to 500 mg/kg
BW), results in significant improvements in whole body
insulin sensitivity. Furthermore, a significant enhance-
ment in insulin-stimulated skeletal muscle glucose
transport and GLUT-4 expression was evident in the
OVX group receiving the highest dose of C. comosa
extract. Because the estrogenic activity of C. comosa
hexane extract has been shown previously [20,21] and
its estrogenic activity in vivo is confirmed here by our
finding that the reduced uterine weight of OVX animals
receiving C. comosa extract was reversed in a dose-
related manner, it is possible that the beneficial effects
of C. comosa on glucose metabolism in the estrogen-
deprived state are attributed by the estrogenic activity of
the extract.
Increasing evidence suggests that abdominal obesity
and concomitant development of inflammation are
major components of insulin resistance, and elevated
levels of pro-inflammatory cytokines secreted from
expanded adipose tissue can negatively modulate insulin
signaling pathways [38]. Recently, it has been reported
that treatment with C. comosa powder significantly
reduced the expression levels of several pro-
inflammatory cytokines in rabbits fed with a high-cho-
lesterol diet [39]. Furthermore, C. comosa extract treat-
ment reduces release of major pro-inflammatory
cytokines in the microglia, peripheral mononuclear cells
and a pro-monocytic cell line [16,17], highlighting the
anti-inflammatory role of C. comosa. Thus the finding
in this study, that treatment with C. comosa extract
reduced the accumulated visceral fat content in OVX
rats, suggests that C. comosa may improve insulin action
by minimizing the source of pro-inflammatory cyto-
kines. Our observation that estrogen-deprivation leads
to atherogenic dyslipidemia is consistent with other ear-
lier reports [40,41]. C. comosa treatment of OVX rats
had favorable effects on plasma lipids, reducing the
absolute levels of TC and LDL and the LDL/TC ratios
while increasing HDL/TC ratios. The reduction in
serum LDL cholesterol following treatment with C.
comosa hexane extract here is consistent with our earlier
studies, in which C. comosa extract decreased LDL and
increased HDL cholesterol levels by increasing choles-
terol excretion and elimination from the body via the
feces [42]. Importantly, the decreased serum TC and
LDL levels as a result of treatment with C. comosa pow-
der in hypercholestorolemic animal were observed with-
out causing liver toxicity [39]. Collectively, we provide
evidence that treatment with C. comosa extract prevents
the development of central adiposity, dyslipidemia,
impaired glucose tolerance and skeletal muscle insulin
resistance that occur as a result of estrogen deficiency.
The mechanisms responsible for its favorable effects
may be attributed by its estrogenic and anti-inflamma-
tory properties.
In addition to demonstrating the beneficial effects of
C. comosa extract treatment, we have further verified
the identity of the active constituent of C. comosa
extract and its metabolic effects. Compound 049, or
(3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol, was found
to be the major compound isolated from the C. comosa
hexane extract [20]. Its estrogenic activity has been
shown both in vitro [20] and in vivo [21], and its rela-
tively weak estrogenic activity in vivo is confirmed here
by our finding that the reduced uterine weight of OVX
animals was only partially reversed by compound 049
treatment. In the present study, the comparable favor-
able outcomes were observed for serum lipid profiles,
visceral fat accumulation, glucose tolerance and skeletal
muscle glucose transport in estrogen-deprived rats trea-
ted with either compound 049 or C. comosa extract,
whereas the body weight gain and energy intake in OVX
rats were significantly reduced only in groups receiving
C. comosa extract. This finding suggests that C. comosa
extract and compound 049 modulated final body
weights and the amount of food intake differently.
Although it remains unknown how compound 049 acts
Prasannarong et al. BMC Complementary and Alternative Medicine 2012, 12:28
http://www.biomedcentral.com/1472-6882/12/28
Page 9 of 11to prevent the progression of insulin resistance in OVX
rats, it possesses weak estrogenic activity which is con-
sistent with the notion that the protective effect of com-
pound 049 against the development of insulin resistance
in the estrogen-deprivation condition may be related to
other unidentified actions and independent to the estro-
genic activity in the regulation of food intake and body
weight. Based on the findings that compound 049 treat-
ment leads to a significant improvement in Akt phos-
phorylation [43] and a reduction in expression of tumor
necrosis factor-a [44] in aortic ring of OVX rats, we
hypothesize that the mechanism underlying the
enhanced whole-body insulin sensitivity and skeletal
muscle insulin action in OVX rats by compound 049
treatment may be attributed to its action on tissues
known to regulate glucose metabolism. While the
opposing effects of the two subtypes of ER in the skele-
tal muscle have been reported, with ERa inducing and
ERb inhibiting GLUT-4 expression [34], it has been
shown that compound 049 is an agonist for ER, and its
biological action is ERa selective [45]. With our finding
here that whole muscle GLUT-4 expression is increased
following treatment with compound 049, it is likely that
compound 049 selectively modulates estrogen receptor
and improves insulin action in the skeletal muscle. The
mechanisms by which compound 049 enhances whole-
body insulin sensitivity and how it affects major meta-
bolic tissues such as the liver and the pancreas are
under investigation.
Conclusions
This investigation indicates that improvements in glu-
cose and lipid metabolism in estrogen-deprived rats
manifest following 12-weeks of treatment with C.
comosa extract, supporting the traditional use of this
natural phytoestrogen as a strategy in relieving insulin
resistance and its related metabolic defects in postmeno-
pausal women. In particular, C. comosa extract effec-
tively prevented the body weight gain, visceral fat
accumulation, abnormal serum lipids, impaired glucose
tolerance and skeletal muscle insulin resistance that
occur as a result of estrogen deficiency. Importantly,
these favorable effects of C. comosa extract on lipid pro-
file, visceral fat content and insulin sensitivity are
demonstrated to be due to its diarylheptanoid derivative.
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